AJMC November 2, 2024
New legislation would clarify rules around value-based contracts in Medicaid, and a new model is expanding access to gene therapies, explained Adam Colborn, JD, of AMCP.
The Medicaid VBPs for Patients Act would clarify value-based contract pricing in Medicaid that aligns with Medicaid’s best price rule, and the new Cell and Gene Therapy Access Model allows for CMS to negotiate a value-based contract for expensive cell and gene therapies on behalf of states, which should expand patient access to these therapies, said Adam Colborn, JD, associate vice president of congressional affairs, AMCP.
This transcript is lightly edited for clarity.
Transcript
What are some of the value-based care programs being tried in Medicaid and how do they differ from the Medicare...
Today's Sponsors
Today's Sponsor